Qandli diabet 2 tur bemorlarda yurak qon tomir kasalliklarini rivojlanishda ortiqcha vaznnig axamiyati va davolashning oʻziga xosligi
Автор: Yusupova Shaxnoza Qodirjanovna
Журнал: Re-health journal.
Статья в выпуске: 3 (23), 2024 года.
Бесплатный доступ
2 tur diabet semizlik bilan bogʻliq kasallikdir. Diabet kasalligiga chalingan bemorlar orasida ortiqcha vazn va semizlik juda keng tarqalgan. Qandli diabet 2 tur bilan ogʻrigan semiz va ortiqcha vaznli bemorlarda yuqori qon bosimi, lipidlar almashinuvi buzilishi va mikroalbuminuriyaning koʻproq uchraydi. Bular esa yaxshi ma’lum boʻlgan yurak-qon tomir kasalliklari xavf omillari hisoblanadi. Diabet kasalligiga chalingan bemorlarda yurak-qon tomir kasalliklari (YuQT) xavfi yuqori boʻlib, bu xavfni kamaytirishda xavf omillarini nazorat qilish muhim ahamiyatga ega.
Qandli diabet, semizlik, ortiqcha vazn, yurak qon tomir kasalliklari
Короткий адрес: https://sciup.org/14130772
IDR: 14130772
Список литературы Qandli diabet 2 tur bemorlarda yurak qon tomir kasalliklarini rivojlanishda ortiqcha vaznnig axamiyati va davolashning oʻziga xosligi
- K. Eeg-Olofsson & J. Cederholm & P. M. Nilsson Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients . Diabetologia (2009) 52:65–73
- Skyler JS, Bakris GL, Bonifacio E et al (2017) Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 66:241–255
- World Health Organisation
- Ridderstrale M, Gudbjornsdottir S, Eliasson B, Nilsson PM, Cederholm J (2006) Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 259:314–322
- 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes; European Heart Journal (2023)
- Carolyn T Bramante,Clare J Lee,Kimberly A Gudzune treatment of obesity in patient with diabetes Pub Med 2017
- Jensen MD, Ryan DH, Apovian CM, et al.. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63:2985–3023 [PubMed] [Google Scholar]
- Cefalu WT, Bray GA, Home PD et al (2015) Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care 38:1567–1582
- Jindal A, Stephen B, Sowers JR. Obesity and the cardiorenal metabolic syndrome: Therapeutic modalities and their efficay in improving the cardiovascular and renal risk factors. Journal of Cardiorenal medicine. . 2012 [PMC free article] [PubMed] [Google Scholar]
- Czernichow S, Knol MJ, Fezeu L, Grobbee DE. Impact of orlistat initiation on cardiovascular treatment use: A 6-year population-based cohort study. Eur J Prev Cardiol. 2012;19(3):484–489. [PubMed] [Google Scholar]
- Luis M Perez-Belmonte,Jaime Sanz-Canovas,Michele Ricci et.all Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice Front. Endocrinol., 24 June 2022
- Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients With Diabetes and Recent Worsening Heart Failure. N Engl J Med (2021) 384(2):117–28. doi: 10.1056/NEJMoa2030183
- Wing RR, Espeland MA, Clark JM et al (2016) Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 39:2318–2318
